Torrent Pharmaceuticals Limited on Tuesday posted an 8 per cent dip in standalone net profit for the quarter ended June 30, at ₹274 crore against ₹298 crore in the corresponding quarter a year ago.
Standalone revenue from operations stood at ₹1,695 crore against ₹1,727 crore in the same period last year.
On a consolidated basis, the company’s net profit for the period stood at ₹330 crore, up 3 per cent, against ₹321 crore in the same quarter last year.
Consolidated revenue from operations stood at ₹2,134 crore ₹2,056 crore).
India revenues grew 18 per cent to ₹1,093 crore, while US revenues were down 29 per cent to ₹266 crore. Revenue from Brazil and Germany were up 9 per cent and 5 per cent respectively at ₹153 crore and ₹260 crore.
Consolidated EBITDA for the quarter stood at ₹717 crore, about 8 per cent higher against ₹664 crore reported in the same period last year.
R&D spend went up 16 per cent during the quarter to ₹125 crore (₹108 crore).
Torrent Pharma shares ended at ₹3,003.75 apiece, down nearly 2.5 per cent from the previous close, on the BSE on Tuesday.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.